

Curriculum Vitae

THOMAS MCKINSEY, PH.D.

123 Anywhere Blvd, No. 456 • Any City, ST 77777

Cell 303-987-7777 • tmckinsey@aol.com

PROFESSIONAL PROFILE

- Accomplished and results-oriented R&D leader with over 20 years of research and 9 years of industrial In Vivo pharmacology experience in cardiovascular, renal, and pulmonary disease.
- Extensive experience with experimental design, statistical analysis, and technical report writing.
- Technical talent and analytical expertise transferable across industries and specialized management practices.
- Capability in synthesizing, reviewing, and analyzing complex data to contribute valuable insight and enhance decision-making processes.
- Regarded for the ability to drive processes; motivate cross-functional teams; and work well under pressure to manage and meet multiple project deadlines.
- An articulate presenter with outstanding interpersonal skills; adept at cross-functional communication, persuasion, and influence.

EDUCATION

- **Doctor of Philosophy (Physiology)**, Medical College of Wisconsin, Milwaukee, WI 1996
RESEARCH ADVISOR: Jeffrey L. Osborn, Ph.D.
DISSERTATION: *Mechanisms of Elevated Renal Vascular Resistance and Reactivity in Chronic Renal Neuroadrenergic Hypertensive Dogs*
- **Master of Science (Exercise Physiology)**, University of Wisconsin, Milwaukee, WI 1989
RESEARCH ADVISOR: Mark S. Sothmann, Ph.D.
THESIS: *Changes in Respiratory Sinus Arrhythmia with Psychological Stress in Men: Effect of Aerobic Capacity and Psychological Dispositions*
- **Bachelor of Science (Zoology)**, University of Wisconsin, Milwaukee, WI 1985

RESEARCH INTERESTS

- Research interests are directed primarily toward sample research in a variety of interrelated areas:
 - Hypertension and Vascular Research
 - Cardiac Disease and Heart Failure
 - Renal Diseases
 - Cardiopulmonary Disease

TECHNICAL SKILLS

- In Vivo Pharmacology
 - Microsurgery
 - Direct organ and system functional evaluation
 - Novel device application and development
 - Non-invasive imaging

- Ex Vivo Pharmacology
 - Microvessel and nephron perfusion
 - Classical receptor / radioligand binding assays
- Histological Analysis
 - Morphometry
 - Quantitative fibrosis

ACADEMIC HONORS AND AWARDS

- **Co-Chair**, APS Translational Physiology Symposium “Novel Approaches in the Treatment of Heart Failure” – *Topic Accepted*, Anaheim, CA; Experimental Biology, 2010.
- **Chairman**, APS Liaison with Industry Symposium “Molecular Imaging of Physiological Processes in Drug Discovery” – New Orleans, LA; Experimental Biology, 2009.
- **Co-Chair**, APS Translational Physiology Symposium “Fibrosis – Physiology, Signaling and Potential Therapeutics” – New Orleans, LA; Experimental Biology, 2009.
- **Key Contributor Award**, Gilead Sciences, Inc., 2007 - 2009.
- **Research Recognition Award**, Global Pharmaceutical Research & Development, Abbott Laboratories, 2003.
- **Research Grant**, National Kidney Foundation, Michigan Affiliate (not accepted), July 1, 2001.
- **Co-Chairman**, FASEB Summer Research Conference: Renal Hemodynamics, Saxson’s River VT, June 2001.
- **Postdoctoral Fellowship Grant**, National Kidney Foundation, Michigan Affiliate (not accepted), July 1, 1999.
- **Postdoctoral Fellowship Grant** (2 Year Award), American Heart Association, Michigan Affiliate, July 1, 1999.
- **American Physiological Society Award for Excellence in Renal Research** (Post-Doctoral Fellow Competition), Experimental Biology Meeting, April 1999.
- **Merck New Investigator Award**, American Heart Association Council for High Blood Pressure Research Meeting, September 1998.
- **Postdoctoral Fellowship Grant**, National Kidney Foundation, Michigan Affiliate, (not accepted), July 1, 1998.
- **Postdoctoral Fellowship Grant**, American Heart Association, Michigan Affiliate, July 1, 1998.
- **Midwest Physiological Society Renal Physiology/Hypertension Award**, Midwest Physiological Society Meeting, June 1996.
- **Proctor & Gamble Professional Opportunity Award**, Water and Electrolyte Homeostasis Section, Experimental Biology Meeting, April 1996.
- **Standing Ovation Award**, Nominated by medical students for outstanding teaching and service, Medical College of Wisconsin, 1994 - 1995.
- **American Physiological Society Award for Excellence in Renal Research** (Graduate Student Competition), Experimental Biology Meeting, April 1995.
- **Caroline tum Suden/Francis A. Hellebrandt Professional Opportunity Award**, Committee on Women in Physiology of the American Physiological Society, spring 1995.
- **Chairman**, First Annual Student's Choice Seminar, Medical College of Wisconsin, September 1994. *Speaker:* Arthur C. Guyton, M.D.
- **Predoctoral Fellowship Grant**, American Heart Association - Wisconsin Affiliate, 1993 - 1994.

ACADEMIC/TEACHING EXPERIENCE

- Biology Learning Skills Workshop and Biological Sciences Tutor 2004 - 2005
Front Range Community College, Westminster, CO
- Laboratory Instructor/Teaching Assistant 1995 - 1997
Mini-Medical School, Medical College of Wisconsin, Milwaukee, WI
- Head of Medical Student Tutoring Service, Freshman Medical Physiology 1992 - 1997
Medical College of Wisconsin, Milwaukee, WI

- Teaching Assistant, Freshman Medical Physiology 1992 - 1997
Medical College of Wisconsin, Milwaukee, WI
- Instructor, Physiology and Pathophysiology 1992 - 1995
LaFarge Lifelong Learning Institute, Milwaukee, WI
- Teaching Assistant, Exercise Physiology, Department of Human Kinetics 1988 - 1989
University of WI-Milwaukee, Milwaukee, WI

HIGHLIGHTS OF PROFESSIONAL EXPERIENCE

Senior Research Scientist II, Gilead Sciences, Inc. (formerly Myogen), Westminster, CO 2008 - Present

- Directed efforts of In Vivo Pharmacology unit to meet overall R&D departmental goals and provide scientific expertise to cross-functional drug discovery teams.
- Contributed extensively to design and execution of preclinical and clinical MOA studies for Endothelin Receptor Antagonist (ERA) teams.
- Served as In Vivo Pharmacology Representative and Advisor to two CKD and IPF Discovery Project Teams.
- Provided crucial proof-of-concept data to enable successful filing and approval of orphan drug application for Ambrisentan use in Idiopathic Pulmonary Fibrosis.
- Executed additional management responsibility, increasing in-line reports to 16 in 2009, including four Ph.D.s, nine research associates, and three animal care technicians.
- Led programming/facility planning for In Vivo Pharmacology expansion and relocation to new facility in Q4 '09.
- Organized, planned, and led Key Opinion Leader (KOL) Symposium to drive decision towards indication for internal CKD drug discovery efforts.
- Successfully developed and validated models of pulmonary, renal fibrosis, and proteinuric renal disease.
- Contributed extensively to Preclinical Pharmacology section of GS-9450 IND to enable timely regulatory submission.

Senior Research Scientist I, Gilead Sciences, Inc. (formerly Myogen), Westminster, CO 2007

- Served as In Vivo Pharmacology Representative to Fibrosis project teams.
- Directly contributed to group increasing to 13 in-line reports in 2007.
- Hired three biologists, two additional Ph.D. scientists, and two contract workers.
- Co-authored necessary documents for successful filing of Gilead-Novartis collaboration milestone payments.
- Led programming/facility planning for In Vivo Pharmacology expansion (~250%) of Phase I Q3 '08 and subsequent Phase II (~170%) additional planned for 2010.
- Developed and validated models of systolic and diastolic heart failure, pulmonary and hepatic/portal hypertension, and fibrotic disease.
- Planned, organized, and led Medical Affairs Advisory Committee KOL Symposium on ERA-mediated edema.
- Served as Preclinical Expert on ERA Comparative Biology team.
- Authored multiple SOPs, including volatile anesthetic use, animal care, and vivarium maintenance to facilitate integration and adoption of Gilead Corporate EH&S mandates.
- Served on due-diligence review team for multiple pulmonary hypertension and renal disease in-licensing opportunities.
- Actively participated in site visits and evaluations of CROs for outsourced research activities.
- Designed, developed, and validated technical advances for direct evaluation and vascular access port methodology for serial evaluation of systemic hemodynamics and humoral biomarkers.
- Designed, developed, and validated a novel device for consistent and reproducible induction of pressure overload; provisional patent issued.

Scientist III, Gilead Sciences, Inc. (formerly Myogen), Westminster, CO 2004 - 2006

- Served as In Vivo Pharmacology Laboratory Group Leader.
- Planned and executed in vivo biochemical screening, proof-of-concept, and disease/compound efficacy studies.
- Developed, evaluated, and validated rodent models (surgical, pharmacological, and genetic) of cardiac failure and pathological hypertrophy.
- Expanded from In Vivo Pharmacology laboratory (~40%) to concurrently house $\leq 1,000$ rats and ≤ 600 mice.
- Reconfigured in Vivo Pharmacology laboratory to enable utilization of multiple direct systemic and cardiac hemodynamic data acquisition systems.
- Supervised transgenic mouse and neonatal rat breeding facilities.
- Performed due diligence on, and directed purchase of specialized cardiac ultrasound (Vevo 770 by VisualSonics; n=2), 32-channel telemetry (DSI/Ponemah), and quantitative histology (AxioImager by Zeiss; n=2) systems.
- Established and validated methodologies for obtaining serial, non-invasive measurements of cardiac morphology, ventricular systolic and diastolic performance.
- Conducted necessary pre-clinical evaluation (Enoximone) and developed detailed study plan for preclinical MOA and new indication studies (Ambrisentan, Darusentan) for Clinical Development Project Team.
- Mentored and supervised up to six direct reports, including Ph.D. scientist and research associates.
- Served as In Vivo Pharmacology Representative/Advisor to four Heart Failure Discovery Project Teams.
- Authored six SRPs (Standard Research Protocols) to optimize alignment of technical staff and training of incoming hires.
- Served as IACUC Chairman, Animal Facilities Manager, and DEA Controlled Substance Liaison.

Associate Research Investigator, Abbott Laboratories, Abbott Park, IL 2003 - 2004

- Planned and executed safety and efficacy pharmacology studies using both *in vivo* and *in vitro* models.
- Served as departmental liaison for Global Anti-Anxiety project team as well as serving on review teams for Renal, Cardiovascular, and Hematologic In-Licensing opportunities.
- Departmental radiation use permit holder.
- Mentored and supervised three direct reports.

Senior Research Pharmacologist, Abbott Laboratories, Abbott Park, IL 2001 - 2002

- Planned, executed, and supervised safety pharmacology studies using conscious and anesthetized in vivo (dogs and non-human primates) cardiovascular models as well as in vitro hematologic models.
- Planned, executed, and supervised efficacy pharmacology studies using conscious and anesthetized in vivo diabetes and renal function models.
- Configured, validated, and supervised studies using non-human primate telemetry-colony.
- Mentored and supervised one direct report.

PATENT APPLICATIONS

Provisional Patents

- Therapeutic Combinations and Methods for Cardiovascular Improvement and Treating Cardiovascular Disease, 8493-000016/US/PS1, Issued February 2008.
- A Device for Producing Uniform Reductions in Blood Vessel Diameter, March 9, 2007.
- Methods for Preventing and/or Treating Renal Fibrosis, Filed U.S. Patent, February 27, 2006.
- Methods for Preventing and/or Treating Renal Hypertrophy, Filed U.S. Patent, February 27, 2006.

PROFESSIONAL DEVELOPMENT

- Completed "Leading and Managing at Gilead" training (4 modules, 2 days each).

PROFESSIONAL AFFILIATIONS

- Chairman, Physiologists in Industry Committee (PIC), American Physiological Society, 2008 - 2010
- Renal Section Steering Committee, American Physiological Society, 2005 - Present
- Careers Committee (PIC Representative), American Physiological Society, 2005 – Present
- Animal Care and Experimentation Committee *ad hoc* member, American Physiological Society, 2008 – Present
- International Society of Nephrology, 2001 - 2004; 2007 - Present
- American Society of Nephrology, 1998 - Present
- Council for High Blood Pressure Research, American Heart Association, 1998 - Present
- American Physiological Society Regular Membership, 1996 - Present
- American Association for the Advancement of Science, 1995 - Present
- Student Medical Association for Animal Research and Teaching (SMAART), 1991 - 1995
- American College of Sports Medicine Student Membership, 1986 – 1989

SCHOLARLY CONTRIBUTIONS

Editorial Activities

- American Journal of Physiology: Renal Physiology Section, Heart and Circulatory Physiology Section, and Regulatory, Integrative, and Comparative Physiology Section.
- American Society of Nephrology Journal
- Kidney International
- Journal of Applied Physiology

Published Web Sites

- Principle Author: “What Industry Physiologists Do” American Physiological Society “Liaison with Industry Committee Web site (<http://www.the-aps.org/committees/liaison>), fall 2006.
- Contributing Author: “Careers in Industry: The Drug Discovery Process” American Physiological Society “Liaison with Industry Committee Web site (<http://www.the-aps.org/committees/liaison>), spring 2006.

Invited Lectures

- Experimental Biology - Corporate Symposium sponsored by VisualSonics: guest lecturer, Cardiac Physiological and Pathophysiological Determinations Using Ultra High-Frequency Ultrasound – Confessions of a Non-Cardiologist, April 2007.
- Medical College of Georgia: Visiting Professor; Department of Pharmacology, Modern Drug Discovery & Development: Differences Between Large and Small Pharma, March 2006.
- Nitromed: Invited Speaker, Renal Vascular and Tubular Mechanisms in Chronic Renal Neuroadrenergic Hypertension, June 2003.
- American Heart Association: Council for High Blood Pressure Research, PI-3-Kinase-Dependent Activation of eNOS Mediates Alpha-2 Receptor Induced Inhibition of Thick Ascending Limb Transport, September 2001.
- FASEB Summer Research Conference: Renal Hemodynamics, How Does Macula Densa NO Inhibit TGF? June 2001.
- Neurohumoral Regulation of Thick Ascending Limb Transport Via Activation of Nitric Oxide Synthase, May 2000.
- Michigan Hypertension Workshop – Gull Lake, Endogenous eNOS-mediated NO Production Inhibits Thick Ascending Limb Transport, May 1999.
- Division of Hypertension and Vascular Research, Henry Ford Hospital, Renal Nitric Oxide: A Role in the Antihypertensive Effects of Aerobic Exercise? June 1998.
- Renal Neuroadrenergic Hypertension Upregulates α_2 Adrenoceptors and Downregulates AT₁ Receptors. April 1997.

- Department of Physiology, Medical College of Wisconsin, Mechanisms of Elevated Renal Vascular Resistance and Reactivity in Renal Neuroadrenergic Hypertensive Dogs, January 1997.
- Chronic Renal Neuroadrenergic Hypertension Produces Volume Contraction and Increased Renal Vascular Reactivity *in Vivo* and *In Vitro*, June 1995.
- Experimental Biology Meeting, Chronic Renal Neuroadrenergic Hypertension Is Associated with Volume Contraction and Increased Renal Vascular Sensitivity to Norepinephrine, April 1995.
- Changes in Renal Vascular Reactivity Are Involved in Renal Neurogenic Hypertension, August 1994.
- Studies on the Mechanisms of Renal Neuroadrenergic Hypertension, July 1993.
- Factors Influencing the Regulation of Renal Adrenoceptors, June 1992.

Published Manuscripts

- Liles, J.T., Ida, K.K., Joly, K.M. Chapo, J., and Plato, C.F. Age exacerbates chronic catecholamine-induced impairments in contractile reserve. *Clin Exp Physiol Pharmacol.* 2010.
- Cavasin, M.A., Semus, H., Pitts, K.R., Peng, Y., Sandoval, J., Chapo, J., and Plato, C.F. Acute effects of endothelin antagonists on hepatic hemodynamics of normal and cirrhotic rats. *Canad J Physiol Pharmacol.* 2010.
- Chapman, M.E., Hu, L., Plato, C.F. and Kohan, D.E. Bioimpedance spectroscopy for the estimation of body fluid volumes in mice. *Am. J. Physiol. – Renal Physiol.* 2010 *In Press.*
- Xin, M., Small, E.M., Sutherland, L.B., Qi, X., McAnally, J., Plato, C.F., Richardson, J.A., Bassel-Duby, R., and Olson, E.N. MicroRNA-143 and -145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. *Genes Dev*, 23(18): 2166-2178, 2009.
- Rybkin, I.I. Kim, M.S., Bezprozvannaya, S. Qi, X., Richardson, J.A., Plato, C.F., Hill, J.A., Bassel-Duby, R., and Olson, E. Regulation of atrial natriuretic peptide by a novel Ras-like protein. *J Cell Biol* 179(3): 527-537, 2007.
- Harrison, B.C., Kim, M-S., van Rooij, E., Plato, C.F., Papst, P.J., Vega, R.B., McAnally, J.A., Richardson, J., Bassel-Duby, R., Olson, E.N., and McKinsey, T. Regulation of cardiac stress signaling by PKD1. *Molec Cell Biol.* 26: 3875-3888, 2006.
- Ortiz, P.A., N.J. Hong, C.F. Plato, M. Varela, and J.L. Garvin. An *in vivo* method for adenovirus-mediated transduction of thick ascending limbs. *Kidney Int.* 63:1141-1149, 2003.
- Ortiz, P., B.A. Stoos, N.J. Hong, D.M. Boesch, C.F. Plato, and J.L. Garvin. High-salt diet increases sensitivity to NO and eNOS expression but not NO production in THALs. *Hypertension* 41(pt. 2): 682-687, 2003.
- Plato, C.F., and J.L. Garvin. α_2 -adrenergic-mediated tubular NO production inhibits thick ascending limb chloride absorption. *Am. J. Physiol. Renal Physiol.* 281:F679-F686, 2001.
- Plato, C.F. α -2 and β -adrenergic receptors mediate NE's biphasic effects on rat thick ascending limb chloride flux. *Am. J. Physiol. Regulatory Integrative Comp. Physiol.* 281: R979-R986, 2001.
- Plato, C.F., D.M. Pollock, and J.L. Garvin. Endothelin inhibits thick ascending limb chloride flux via ET_B receptor-mediated NO release. *Am. J. Physiol. Renal Physiol.* 279: F326-F333, 2000.
- Plato, C.F., E.G. Shesely, and J.L. Garvin. eNOS mediates L-arginine-induced inhibition of thick ascending limb chloride flux. *Hypertension* 35: 319-323, 2000.
- García, N.H., C.F. Plato, B.A. Stoos, and J.L. Garvin. Nitric oxide-induced inhibition of transport by thick ascending limbs from Dahl salt-sensitive rats. *Hypertension* 34: 508-513, 1999.
- Garcia, N.H., C.F. Plato, and J.L. Garvin. Fluorescent determination of chloride in nanoliter samples. *Kidney Int.* 55: 321-325, 1999.
- Plato, C.F., and J.L. Garvin. Nitric oxide, endothelin and nephron transport: potential interactions. *Clin. Exp. Pharmacol. Physiol.* 26: 262-268, 1999.
- Plato, C.F., B.A. Stoos, D. Wang, and J.L. Garvin. Endogenous nitric oxide inhibits chloride transport in the thick ascending limb. *Am. J. Physiol.* 276: F159-F163, 1999.
- Osborn, J.L., C.F. Plato, E. Gordin, and X.R. He. Long-term increases in renal sympathetic nerve activity and hypertension. *Clin. Exp. Physiol. Pharmacol.* 24: 635-641, 1997.
- Plato, C.F., and J.L. Osborn. Chronic renal neuroadrenergic hypertension is associated with increased renal norepinephrine sensitivity and volume contraction. *Hypertension* 28: 1034-1040, 1996.

Manuscripts Submitted for Publication

- Bush, E.W., McQuire, L., Gamber, G., Plato, C.F., Pitts, K., Schreiber, K., McKinsey, T.A., Castonguay, L.A., Gorczynski, R.J., and Melvin, L. Novel thyromimetics lacking structural similarity to thyroid hormone regulate cardiac alpha myosin heavy chain expression. *Med Chem Lett. Submitted.*
- Meredith, E., Dobler, M., Yoon, T., Jewell, C., Siska, S., Zhu, N., Yang, L., Patnaik, A., Pancost, M., Miranda, K., Rao, C., von Matt, A., Qian, M., Shi, J., Baryza, J., West, L., Vega, R., Beattie, K., Rozhitskaya, O., Zhang, J-H., Lee, W., Hosagrahara, V., van Eis, M., Gaul, C., Rajaraman, V., Lehmann, H.J., Ruppen, T., Koch, K., Pagratis, N., Melvin, L., Plato, C., McKinsey, T., and Monovich L. Identification of orally available naphthyridine protein kinase D inhibitors. *J Med. Chem. Submitted.*
- Plato, C.F., Cavasin, M.A., Perry, A.R., Joly, K.M., and K.R. Pitts. Pan-HDAC inhibition dose-dependently prevents high salt induced cardiac hypertrophy, fibrosis, and diastolic dysfunction in Dahl S rats. *Am. J Physiol – Heart Circ Physiol. Submitted.*
- Hu L., Maslanik, T., Zerebeckyj, M., and Plato, C.F. Evaluation of Bioimpedance Spectroscopy for the measurement of body fluid volumes in rats. *J. Appl Physiol Submitted.*
- Plato, C.F., Joly, K.M., Glascock, C., and Pitts, K.R. HDAC inhibition augments thyroid hormone induced increases in cardiac performance in hypothyroid rats. *Am J Physiol - Heart Circ Physiol. Submitted.*
- Plato, C.F. and J.L. Osborn. Altered kidney vascular reactivity in chronic renal neuroadrenergic hypertension. *Clin. Exp. Pharmacol. Physiol. Submitted.*
- Plato, C.F., G. Bachowski, X.-R. He, and J.L. Osborn. Renal neuroadrenergic hypertension upregulates α_2 adrenoceptors and downregulates AT₁ receptors. *Am. J. Physiol. Regulatory Integrative Comparative Physiol. Submitted.*
- Plato, C.F. and J.L. Osborn. Chronic renal neuroadrenergic hypertension alters renal vascular reactivity *in vitro*. *Am. J. Physiol. Regulatory Integrative Comparative Physiol. Submitted.*
- Plato, C.F., B.F. Cox, and G.A. Reinhart. Disparate renal hemodynamic responses to dopamine D₃-Receptor activation in STZ-diabetic and normal rats. *J Cardiovasc Pharm. Submitted.*

Manuscripts in Preparation

- Plato, C.F., Perry, A.M., Lemon, D., Glascock, C.B., Peng, Y., Bush, E.W., and Hartman, J.C. Time-course of downregulation of cardiac alpha-myosin heavy chain and dose-dependent effects of exogenous thyroid hormone on cardiac performance in hypothyroid rats. *J Cardiovasc Pharm.*
- Plato, C.F., Perry, A.M., Schonewald, M., Pitts, K.A., Glascock, C.B., Peng, Y., Lemon, D., Bush, E.W., McKinsey, T., Hartman, J.C., and Gorczynski, R.J. Novel thyromimetic compound LCJ-810 dose-dependently increases in cardiac performance and alpha-myosin heavy chain expression in hypothyroid rats. *J Pharmacol Exp Ther.*
- Plato, C.F., Rutledge, A.R., Glascock, C.B., Peng, Y., Pitts, K.A., Bush, E.W., and Hartman, J.C. High Salt Diet Exacerbates Isoproterenol-Induced Increases in Heart Weight Index and Downregulation of α -Myosin Heavy Chain Expression. *Am. J. Physiol. Regulatory Integrative Comparative Physiol.*
- Plato, C.F., Rutledge, A.R., Schonewald, M., Glascock, C.B., Peng, Y., Pitts, K.A., Bush, E.W., Hartman, J.C., McCune, S.M., and Gorczynski, R.J. Strain-dependent cardiac responses to pressure-overload in male rats. *Circulation.*
- Plato, C.F., Rutledge, A.R., Schonewald, M., Glascock, C.B., Peng, Y., Pitts, K.A., Bush, E.W., Hartman, J.C., McCune, S.M., and Gorczynski, R.J. Rapamycin attenuates and regresses catecholamine-induced cardiac hypertrophy in the absence of blood pressure lowering effects. *Circ Res.*
- Plato, C.F., Perry, A.R., Pitts, K.A., Bush, E.W., Hartman, J.C., and Gorczynski, R.J. A novel method for producing uniform pressure-overload and cardiac hypertrophy in rats. *Am. J Physiol. Heart Circ Physiol.*
- Plato, C.F., Perry, A.R., Joly, K.M., McKinsey, T.A., Pitts, K.R. Hartman, J.C., and Gorczynski, R.J. Effects of high salt intake on pressure overload induced cardiac hypertrophy and dysfunction. *Circ Res.*

Abstracts

- Hu, L. and C.F. Plato. Sitaxsentan (SIT) Increases Extracellular Fluid Volume (ECFV) in both Normal Salt (NS) and High Salt-Fed (HS) Dahl S (DS) rats. *Oral presentation given at ET-11 Meeting, Montreal, CA, September 9-12, 2009.*
- Cavasin, A.C., Y. Peng, J. Sandoval, J. Chapo, K.R. Pitts, and C.F. Plato. Acute effects of endothelin antagonists on hepatic hemodynamics of normal and cirrhotic rats. *Poster presented at ET-11 Meeting, Montreal, CA, September 9-12, 2009.*
- Liles, J.T., K. Ida, K.M. Joly, J. Chapo, Y. Peng, and C.F. Plato. Age exacerbates chronic catecholamine-induced impairments in contractile reserve. *FASEB Journal 23: 812.06, 2009.*
- Plato, C.F., K.M. Joly, C. Glascock, and K.R. Pitts. Histone deacetylase inhibition augments thyroid hormone (T₃)-induced increases in cardiac performance in hypothyroid rats. *FASEB Journal 23: 812.12, 2009.*
- Plato, C.F., Rutledge, A.R., Glascock, C.B., Peng, Y., Bowbeer, H., Bush, E.W., and Hartman, J.C. High Salt Diet Exacerbates Isoproterenol-Induced Increases in Heart Weight Index and Downregulation of α -Myosin Heavy Chain Expression. *AHA Basic Cardiovascular Sciences Conference, Keystone, CO, July 2005.*
- Plato, C.F., B.F. Cox, and G.A. Reinhart. Dopamine D₃-receptor activation produces hyperfiltration in normal but not streptozotocin-induced (STZ) diabetic rats. *FASEB Journal 17: A587.23, 2003.*
- Ortiz, P., B.A. Stoos, N.J. Hong, D.M. Boesch, C.F. Plato, and J.L. Garvin. High-salt diet increases sensitivity to NO and eNOS expression but not NO production in THALs. *Hypertension.*
- Plato, C.F. High salt diet increases thick ascending limb eNOS expression and inhibitory effects of L-arginine on chloride flux. *J. Am. Soc. Nephrol. 12, 2001.*
- Plato, C.F. PI-3-kinase-dependent activation of eNOS mediates alpha-2 receptor induced inhibition of thick ascending limb transport. *Hypertension, 2001.*
- Plato, C.F. Norepinephrine's biphasic effects on cortical thick ascending limb (cTHAL) chloride flux are differentially mediated by alpha-2 and beta-adrenoceptors. *J. Am. Soc. Nephrol. 11: 36A, 2000.*
- Plato, C.F., and J.L. Garvin. Alpha-2 adrenoceptors inhibit and beta-adrenoceptors stimulate chloride flux in the cortical thick ascending limb (cTHAL). *FASEB J. 14: A342, 2000.*
- Plato, C.F., and J.L. Garvin. Alpha-2 adrenoceptors inhibit chloride flux in the cortical thick ascending limb (THAL) via activation of nitric oxide synthase. *J. Am. Soc. Nephrol. 10: 41A, 1999.*
- Plato, C.F., and J.L. Garvin. Endothelial nitric oxide synthase mediates L-arginine induced inhibition of mouse thick ascending limb chloride flux. *Hypertension 34: 360, 1999.*
- Plato, C., B. Stoos, and J. Garvin. Endothelin inhibits thick ascending limb transport by increasing endogenous production of NO. *Hypertension 33: 1305, 1999.*
- Plato, C.F., and J.L. Garvin. Endothelin inhibits chloride flux in the cortical thick ascending limb (cTHAL) via activation of the ET_B subtype receptor. *FASEB J. 13: A724, 1999.*
- Plato, C.F., and J.L. Garvin. Endothelin inhibits thick ascending limb (THAL) chloride flux via production of NO. *J. Am. Soc. Nephrol. 9: 42A, 1998.*
- Plato, C.F., D. Wang, and J.L. Garvin. Endogenous NO inhibits chloride flux in the thick ascending limb. *Hypertension 32: 616, 1998.*
- Plato, C. and J. Garvin. Regulation of distal nephron transport by NO. Presented at Renal Hemodynamics: Integration of Endothelial, Epithelial and Vascular Control Mechanisms. 1998 FASEB Summer Research Conference, Saxtons River, Vt., June 27 - July 2, 1998.
- Osborn, J.L. and C.F. Plato. Renal neuroadrenergic hypertension caused by factors unrelated to angiotensin II. *J. Am. Soc. Nephrol. 8: A1402, 1997.*
- Plato, C.F., X.-F. Li, and J.L. Osborn. Localization of renal α -adrenoceptor subtypes: Role in renal neuroadrenergic hypertension. *J. Am. Soc. Nephrol. 8:A1404, 1997.*
- Plato, C.F., G.J. Bachowski, and J.L. Osborn. Renal neuroadrenergic hypertension upregulates α_2 adrenoceptors and downregulates AT₁ receptors. *FASEB J. 11: A42, 1997.*
- Osborn, J.L., D.P. Whitehouse, and C.F. Plato. Intrarenal AT₁ receptor blockade enhances renal autoregulation in anesthetized dogs. *FASEB J. 10: A372, 1996.*
- Plato, C.F. and J.L. Osborn. Long-term renal neuroadrenergic hypertension alters renal vascular reactivity. *FASEB J. 10: A635, 1996.*

- Plato, C.F. and J.L. Osborn. Chronic renal neuroadrenergic hypertension is associated with volume contraction and increased renal vascular sensitivity to norepinephrine. *FASEB J.* 9: A296, 1995.
- Parker, T.A., Plato, C.F., and J.L. Osborn. Neurogenic control of intrarenal hemodynamics and renal function during AII blockade with losartan. *FASEB J.* 8: A581, 1994.
- Plato, C.F., J.H. Lombard, and J.L. Osborn. Elevated adrenergic sensitivity of renal vasculature is pressure dependent. *FASEB J.* 8: A582, 1994.
- Wenzler, R.B., L.M. Sheldahl, F.E. Tristani, J.L. Christie, A.B. Gustafson, S.G. Levandoski, and C.F. Plato. Effect of age on adaptation to aerobic exercise training. *J. Am. Coll. Cardiol.* 9: 235A, 1987.
- Hoffman, M.D., L.M. Sheldahl, R.B. Wenzler, C.F. Plato, S.G. Levandoski, S.G., J.H. Kalbfleisch, J.S. Dunnick, and F.E. Tristani. Cardiovascular responses in paraplegics during exercise with lower extremity compression. *Clin. Res.* 35: 287A, 1987.
- Wenzler, R.B., L.M. Sheldahl, F.E. Tristani, A.B. Gustafson, S.G. Levandoski, J.L. Christie, J.L., and C.F. Plato. Effect of age on training adaptability to aerobic exercise. *Monogr. AHA* 74 (Suppl 4, Part 2): 1998, 1986.
- Levandoski, S.G., J.L. Christie, L.M. Sheldahl, F.E. Tristani, and C.F. Plato. Comparison of cardiorespiratory and metabolic responses to upright treadmill and supine bicycle graded exercise. *Clin. Res.* 34: 320A, 1986.

Reports

- Acute Renal Excretory and Cardiovascular Responses to Vasopressin V_{1b} Antagonism in Conscious Rats, September 2003.
- Effects of Abbott-425769 on Hemodynamic and Electrocardiographic Function in the Conscious Monkey, February 2003.
- Effects of Abbott-408778 and Abbott-408892 on Human Platelet Function *in vitro*, December 2002.
- Effects of Serotonin 5HT_{1a} Receptor Agonists on systemic Hemodynamics in the Conscious Cynomolgus Monkey, May 2002.
- Effects of ICI-25651 on Hemodynamic Responses to Endotoxin Lipopolysaccharide in Awake Rabbits, November 1990.